<DOC>
	<DOC>NCT00117234</DOC>
	<brief_summary>The purpose of this study was to evaluate the effect of treatment with darbepoetin alfa on peak oxygen consumption (peak VO2) in subjects with symptomatic CHF and anemia.</brief_summary>
	<brief_title>Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Symptomatic CHF for at least 3 months Reduced left ventricular ejection fraction Stable heart failure medication Peak VO2 less than or equal to 16 ml/kg/min Hemoglobin concentration between 9.0 and 12.0 g/dL Hypertension Unstable angina pectoris or recent myocardial infarction Likely to receive cardiac transplant Unable to do cardiopulmonary exercise testing Major organ transplant (e.g., lung, liver, heart) or renal replacement therapy (e.g., dialysis) Recent or current treatment for malignancy Systemic hematologic disease Anemia due to acute or chronic bleeding Recent EpogenÂ® or darbepoetin alfa therapy Recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>low hemoglobin</keyword>
	<keyword>anemia</keyword>
	<keyword>CHF</keyword>
	<keyword>Symptomatic Congestive Heart Failure (CHF)</keyword>
</DOC>